Recent Updates
Recently added Catalysts

CPC-201

Phase 2

Alzheimer's Disease | Small molecule | Other |AbbVie Inc.|Last Updated: Jun 4, 2020

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment41

FDA Designations

No designations recorded

Clinical trial landscape

CPC-201 · 2 trials · 2 indications

Phase 2 2
NCT02434666Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07Dementia of the Alzheimer's Type
COMPLETED21 Analytics
NCT02185053A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type DementiaAlzheimer's Disease
COMPLETED41 Analytics
PHASE2COMPLETED
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
Dementia of the Alzheimer's TypeUnlock trial analytics
PHASE2COMPLETED
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
Alzheimer's DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

safety and tolerability of the maximum tolerated dose (MTD) of CPC-201 (adverse events)
6 months

To evaluate the safety labs and adverse events from baseline, during the study and at the end of the study.

Donepezil Maximum Tolerated Dose (MTD)
6 months

Number of participants who reached Donepezil Maximum Tolerated Dose of 40 mg/day (highest allowed per protocol) at the end of donepezil dose titration phase and at the end of the maintenance phase.

Secondary Endpoints

safety and tolerability of CPC-201 20mg/day (adverse events)
6 months
Number of Subjects With Any TEAEs
6 months
Donepezil Plasma Concentration at Maximum Tolerated (MTD) or Maximum Allowable Dose
Day 1 (baseline) to end of study
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CPC-201EXPERIMENTAL -

Interventions

NameTypeDescription
CPC-201DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to 89 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: 1. Have signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed c...

Countries:United States
Unlock Eligibility Criteria